Literature DB >> 15871131

Low accumulation of L90M in protease from subtype F HIV-1 with resistance to protease inhibitors is caused by the L89M polymorphism.

Alexandre Calazans1, Rodrigo Brindeiro, Patricia Brindeiro, Hugo Verli, Monica B Arruda, Luis Manuel Felipe Gonzalez, Jorge A Guimaraes, Ricardo Sobhie Diaz, Octavio A C Antunes, Amilcar Tanuri.   

Abstract

BACKGROUND: This work evaluates the role of subtype F human immunodeficiency virus type 1 (HIV-1) protease (PR) substitutions L89M and L90M in viral replication and resistance to PR inhibitors (PIs).
METHODS: Subtype B and F PR genes were subjected to site-directed mutagenesis, to create and reverse the methionine at positions 89 and 90. Viruses were re-created in cell culture, and their replicative capacity was assessed by fitness assay. Generated viruses were also phenotyped for PI resistance.
RESULTS: The subtype F clone (89M90L) showed a replicative capacity comparable to that of the PI-susceptible subtype B clone (89L90L) and was more fit than the L89M mutated subtype B clone (89M90L). Both 89M90M subtype B and F clones presented the lowest fitness s values. The L89M mutation impacted phenotypic resistance to all PIs in half of the subtype F isolates but not in the subtype B isolates. Subtype F isolates presented a phenotypic profile similar to that of subtype B isolates when the M89L mutation was introduced.
CONCLUSION: The L89M mutation in subtype F viruses is a high genetic barrier to the accumulation of the L90M resistance mutation and can function as a resistance mutation, depending on the presence of other polymorphisms in the subtype F PR backbone.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15871131     DOI: 10.1086/430002

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  17 in total

1.  Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy.

Authors:  Maria Mercedes Santoro; Claudia Alteri; Luigi Ronga; Philippe Flandre; Lavinia Fabeni; Fabio Mercurio; Roberta D'Arrigo; Caterina Gori; Guido Palamara; Ada Bertoli; Federica Forbici; Romina Salpini; Evangelo Boumis; Valerio Tozzi; Ubaldo Visco-Comandini; Mauro Zaccarelli; Margriet Van Houtte; Theresa Pattery; Pasquale Narciso; Andrea Antinori; Francesca Ceccherini-Silberstein; Carlo Federico Perno
Journal:  AIDS Res Hum Retroviruses       Date:  2012-04-18       Impact factor: 2.205

Review 2.  NeuroAIDS in Brazil.

Authors:  Ronald J Ellis; Jeymohan Joseph; Ségio Montiero de Almeida
Journal:  J Neurovirol       Date:  2007-04       Impact factor: 2.643

Review 3.  HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

Authors:  Robert W Shafer; Jonathan M Schapiro
Journal:  AIDS Rev       Date:  2008 Apr-Jun       Impact factor: 2.500

Review 4.  Consensus drug resistance mutations for epidemiological surveillance: basic principles and potential controversies.

Authors:  Robert W Shafer; Soo-Yon Rhee; Diane E Bennett
Journal:  Antivir Ther       Date:  2008

5.  Global analysis of sequence diversity within HIV-1 subtypes across geographic regions.

Authors:  Austin Huang; Joseph W Hogan; Sorin Istrail; Allison Delong; David A Katzenstein; Rami Kantor
Journal:  Future Virol       Date:  2012-05       Impact factor: 1.831

6.  Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008).

Authors:  Jorge L Martinez-Cajas; Nitika P Pai; Marina B Klein; Mark A Wainberg
Journal:  J Int AIDS Soc       Date:  2009-06-30       Impact factor: 5.396

7.  The challenge of antiretroviral drug resistance in HIV-1-infected children.

Authors:  Robert W Shafer
Journal:  J Pediatr (Rio J)       Date:  2009 Mar-Apr       Impact factor: 2.197

Review 8.  Clinical significance of human immunodeficiency virus type 1 replication fitness.

Authors:  Carrie Dykes; Lisa M Demeter
Journal:  Clin Microbiol Rev       Date:  2007-10       Impact factor: 26.132

Review 9.  HIV-1 antiretroviral resistance: scientific principles and clinical applications.

Authors:  Michele W Tang; Robert W Shafer
Journal:  Drugs       Date:  2012-06-18       Impact factor: 9.546

10.  The Influence of HIV-1 Subtype in the Response to Therapeutic Dendritic Cell Vaccine.

Authors:  Valéria Ferreira; Patrícia Moura; Sergio Crovella; Ricardo Sobhie Diaz; Adauto Castelo Filho; Ricardo Ximenes; Luiz Cláudio Arraes
Journal:  Open AIDS J       Date:  2012-12-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.